JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$3.21B |
| 2 |
Arthur J. Gallagher & Co
AJG
|
+$2.24B |
| 3 |
Walt Disney
DIS
|
+$2.18B |
| 4 |
Walmart Inc
WMT
|
+$1.96B |
| 5 |
McDonald's
MCD
|
+$1.91B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$2.77B |
| 2 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$2.64B |
| 3 |
Vanguard Long-Term Treasury ETF
VGLT
|
+$2.5B |
| 4 |
iShares Broad USD High Yield Corporate Bond ETF
USHY
|
+$2.23B |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 24.61% |
| 2 | Technology | 23.17% |
| 3 | Financials | 10.12% |
| 4 | Consumer Discretionary | 9.84% |
| 5 | Healthcare | 7.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4226
Overlay Shares Short Term Bond ETF
OVT
$59.9M
| $1.4M | ﹤0.01% |
63,584
+60,932
| +2,298% | +$1.36M |
2023 Q3
5 quarters
|
|
4227
DocGo
DCGO
$36.6M
| $1.39M | ﹤0.01% |
328,796
+218,941
| +199% | +$844K |
2022 Q2
10 quarters
|
|
4228
CALL
BridgeBio Pharma
BBIO
$13.1B
| $1.39M | ﹤0.01% |
+50,600
| New | +$1.31M |
2024 Q4
0 quarters
|
|
|
ONL
4229
Orion Office REIT
ONL
$137M
| $1.39M | ﹤0.01% |
373,925
+114,171
| +44% | +$449K |
2021 Q4
12 quarters
|
|
4230
PureCycle Technologies
PCT
$882M
| $1.38M | ﹤0.01% |
134,965
+8,716
| +7% | +$101K |
2021 Q2
14 quarters
|
|
4231
MediaAlpha
MAX
$510M
| $1.38M | ﹤0.01% |
122,386
+42,315
| +53% | +$609K |
2020 Q4
16 quarters
|
|
4232
Mercer International
MERC
$17.2M
| $1.38M | ﹤0.01% |
212,388
+105,873
| +99% | +$693K |
2024 Q3
1 quarter
|
|
|
LIF
4233
Life360
LIF
$3.51B
| $1.38M | ﹤0.01% |
33,421
+20,367
| +156% | +$897K |
2024 Q2
2 quarters
|
|
|
GDEN
4234
DELISTED
Golden Entertainment
GDEN
| $1.38M | ﹤0.01% |
43,604
+11,742
| +37% | +$373K |
2017 Q4
28 quarters
|
|
4235
Clearfield
CLFD
$455M
| $1.37M | ﹤0.01% |
44,251
+3,174
| +8% | +$107K |
2017 Q4
28 quarters
|
|
4236
Atea Pharmaceuticals
AVIR
$411M
| $1.37M | ﹤0.01% |
409,259
+314,015
| +330% | +$1.04M |
2020 Q4
16 quarters
|
|
4237
Voyager Therapeutics
VYGR
$151M
| $1.37M | ﹤0.01% |
241,634
-20,300
| -8% | -$131K |
2017 Q3
29 quarters
|
|
4238
Beyond Meat
BYND
$142M
| $1.37M | ﹤0.01% |
12,127
+11,104
| +1,085% | +$1.77M |
2019 Q2
22 quarters
|
|
4239
Woori Financial
WF
$18.5B
| $1.37M | ﹤0.01% |
43,724
+41,459
| +1,830% | +$1.43M |
2015 Q4
36 quarters
|
|
4240
State Street SPDR Bloomberg International Corporate Bond ETF
IBND
$439M
| $1.36M | ﹤0.01% |
48,111
+9,107
| +23% | +$267K |
2023 Q3
5 quarters
|
|
4241
Clover Health Investments
CLOV
$2.33B
| $1.36M | ﹤0.01% |
432,268
+273,348
| +172% | +$977K |
2024 Q3
1 quarter
|
|
4242
Definitive Healthcare
DH
$99.6M
| $1.36M | ﹤0.01% |
331,264
+109,174
| +49% | +$477K |
2021 Q3
13 quarters
|
|
4243
Greenlight Captial
GLRE
$481M
| $1.36M | ﹤0.01% |
97,210
+48,564
| +100% | +$689K |
2017 Q4
28 quarters
|
|
4244
CS Disco
LAW
$271M
| $1.36M | ﹤0.01% |
272,250
+73,504
| +37% | +$427K |
2021 Q3
13 quarters
|
|
4245
Anika Therapeutics
ANIK
$256M
| $1.36M | ﹤0.01% |
82,491
+66,982
| +432% | +$1.32M |
2015 Q4
36 quarters
|
|
|
MGIC
4246
DELISTED
Magic Software Enterprises
MGIC
| $1.36M | ﹤0.01% |
112,782
+19,616
| +21% | +$226K |
2021 Q1
15 quarters
|
|
4247
iShares MSCI USA Size Factor ETF
SIZE
$421M
| $1.36M | ﹤0.01% |
9,136
+6,005
| +192% | +$914K |
2022 Q4
8 quarters
|
|
|
TBRG
4248
DELISTED
TruBridge
TBRG
| $1.34M | ﹤0.01% |
68,189
-44,051
| -39% | -$679K |
2016 Q3
33 quarters
|
|
|
EB
4249
DELISTED
Eventbrite
EB
| $1.34M | ﹤0.01% |
399,507
+257,462
| +181% | +$854K |
2019 Q1
23 quarters
|
|
4250
Northrim BanCorp
NRIM
$551M
| $1.34M | ﹤0.01% |
68,772
+46,056
| +203% | +$881K |
2023 Q1
7 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2024 Portfolio in Review
As of Q4 2024, JP Morgan Chase held 7,917 positions worth $1.34T, up 2.1% from $1.32T the previous quarter. Its ten largest holdings account for 24% of the portfolio.
JP Morgan Chase's Q4 2024 filing shows 509 new, 3,351 increased, 2,465 reduced and 522 closed positions. Its largest new stake was Primo Brands: 3,989,501 shares worth $123M. The largest sale was Eli Lilly, an estimated $2.77B.
By sector, the portfolio is most concentrated in Miscellaneous at 25% of assets, up from 24% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q4 2024 buy was Primo Brands: 3,989,501 shares worth $123M.
- JP Morgan Chase added most to Broadcom in Q4 2024, an estimated $3.21B increase.
- JP Morgan Chase's biggest Q4 2024 reduction was Eli Lilly, cutting an estimated $2.77B.
- JP Morgan Chase fully exited Stericycle Inc in Q4 2024, selling an estimated $183M.
- JP Morgan Chase's ten largest holdings make up 24% of its $1.34T portfolio in Q4 2024.
- JP Morgan Chase opened 509 new positions and closed 522 in Q4 2024.
- JP Morgan Chase's portfolio value rose 2.1% quarter-over-quarter to $1.34T.
Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.